Long‐Acting In Situ Cancer Vaccines by Oncolytic STING‐Activating Microgels
Small · 2025
DOI: 10.1002/smll.202503561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Hujing Tan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Polymers Laboratory, and Jiangsu Key Laboratory of Advanced Functional Polymer Materials, College of Chemistry, Chemical Engineering and M…. Hauptthemen laut MEDLINE: Cancer Vaccines, Microgels, Membrane Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key R&D Program of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
In situ cancer vaccines exploiting endogenous multiple antigens directly from tumors to elicit broad immune responses hold great potential in cancer treatment. However, the feeble antigen presentation and hostile immune microenvironments pose severe challenges to acquiring clinical benefits. Here, oncolytic STING‐activating microgels (OSAM) that release oncolytic peptide LTX‐315 and STING adjuvant diABZI in a sustained manner (>4 weeks) have been developed to elicit long‐acting and powerful antitumor immunity. OSAM induced significant upregulation of MHC I and substantial activation of dendritic cells for more than one week. One single intratumoral administration of OSAM markedly promoted the infiltration of cytotoxic T lymphocytes and natural killer cells, which combining with anti‐CTLA‐4 microgels afforded exceptional therapeutic benefits in several different murine tumor models with a cure rate of 40%–71%. These oncolytic STING‐activating microgels introduce a new and powerful strategy to in situ cancer vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Polymers Laboratory, and Jiangsu Key Laboratory of Advanced Functional Polymer Materials, College of Chemistry, Chemical Engineering and Materials Science, and State Key Laboratory of Radiation Medicine and P…
ORCID-Profile: Chao Deng
Förderung
- National Natural Science Foundation of China
- National Key R&D Program of China
- National Key Research and Development Program of China
Zitieren
APA
Tan, H., Guo, J., Wang, Y., Chen, W., Zhong, Z., & Deng, C. (2025). Long‐Acting In Situ Cancer Vaccines by Oncolytic STING‐Activating Microgels. Small. https://doi.org/10.1002/smll.202503561
Vancouver
Tan H, Guo J, Wang Y, Chen W, Zhong Z, Deng C. Long‐Acting In Situ Cancer Vaccines by Oncolytic STING‐Activating Microgels. Small. 2025. doi:10.1002/smll.202503561
BibTeX
@article{Tan2025,
author = {Tan, Hujing and Guo, Jiakun and Wang, Yan and Chen, Wanting and Zhong, Zhiyuan and Deng, Chao},
title = {Long‐Acting In Situ Cancer Vaccines by Oncolytic STING‐Activating Microgels},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202503561}
}
EUVIMED